Search Result for:
Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease
Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still’s disease (AOSD), the…
View Resource
TNR Grand Rounds – Cytokine Storm Syndromes
This week’s Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama –…
View Resource
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still’s disease (AOSD) based on…
View Resource
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Still’s disease is an autoinflammatory disease characterized by spiking fever, rash, polyarthralgia, sore throat…
View Resource
Still’s Disease Following COVID-19 Vaccination
Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory…
View Resource
Canakinumab Use in Periodic Febrile Disorders
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor…
View Resource
ACR20 – Autoinflammatory & Still's Disease Panel
This podcast features a discussion of autoinflammatory and Still’s disease abstracts from virtual ACR…
View Resource